Yes, there are pills for eczema. Two oral medications, upadacitinib (Rinvoq) and abrocitinib (Cibinqo), received FDA approval specifically for moderate-to-severe atopic dermatitis in 2022. Beyond these newer options, several older immunosuppressant pills have been used off-label for eczema for years. The catch: oral eczema treatments are reserved for people whose skin hasn’t responded well enough to creams and other topical therapies.
FDA-Approved Oral Eczema Medications
Upadacitinib and abrocitinib belong to a class called JAK inhibitors. They work by blocking specific enzymes inside your cells that drive the inflammation behind eczema flares. Unlike topical treatments that target the skin’s surface, these pills dial down the immune overreaction from the inside, which makes them effective for widespread or stubborn eczema that creams can’t control.
Both drugs are taken once daily. In clinical trials comparing them head-to-head against the injectable biologic dupilumab, patients on the oral JAK inhibitors saw faster improvement. By just two weeks, roughly twice as many patients on the pills had achieved a 75% reduction in their eczema severity score compared to those on the injection. By week 12, the oral medications still held that edge. In one major trial (JADE COMPARE), abrocitinib at its higher dose outperformed dupilumab across multiple measures, including itch relief and overall skin clearance.
These medications are specifically approved for adults with moderate-to-severe eczema who haven’t gotten adequate results from other treatments. They’re not first-line options you’d get at a routine visit for mild eczema.
Older Immunosuppressant Pills
Before JAK inhibitors arrived, dermatologists already had several oral options they prescribed off-label for severe eczema. “Off-label” means the drugs are FDA-approved for other conditions but have enough evidence behind them that doctors use them for eczema too. The most common ones include cyclosporine, methotrexate, azathioprine, and mycophenolate mofetil. All are approved for use in both children and adults with moderate-to-severe eczema, though none were originally designed for it.
Cyclosporine tends to work relatively quickly and is often used as a short-term bridge, typically for three to six months. The risk of side effects, particularly kidney problems and high blood pressure, increases the longer you stay on it, so most doctors taper patients off after that window. Methotrexate, on the other hand, is better suited for longer-term use. It’s one of the most commonly prescribed systemic drugs for eczema worldwide, generally well tolerated, and effective over extended periods. Both require regular blood work to monitor for organ stress.
What About Oral Steroids?
Prednisone and other oral corticosteroids can knock down an eczema flare fast, but guidelines treat them as a last resort for short bursts only. The reason: they come with a well-documented rebound problem. Once you stop, your eczema often returns worse than it was before, with flushed, burning skin, intense itching, swelling, and heavy skin shedding. This cycle can become self-reinforcing, making you feel dependent on the medication just to stay at your baseline.
Prolonged or repeated courses also carry risks for bone density, blood sugar, weight gain, and mood changes. For these reasons, oral steroids are not considered a real long-term solution for eczema, even though they’re sometimes the quickest way to get a severe flare under control while transitioning to a safer maintenance therapy.
Safety Concerns With JAK Inhibitors
The newer oral pills are effective, but they carry serious safety warnings that factor into whether they’re right for you. The FDA requires its strongest warning label (a boxed warning) on JAK inhibitors, citing increased risks of serious heart-related events, certain cancers including lymphoma and lung cancer, blood clots, and, in rare cases, death. These risks are especially relevant if you smoke or have a history of heart attack, stroke, blood clots, or other cardiovascular problems.
More common, less severe side effects include upper respiratory infections (colds, sinus infections), headaches, nausea, diarrhea, acne, cold sores, shingles, increased cholesterol, and elevated blood pressure. Your doctor will likely order blood tests before starting treatment and at regular intervals to monitor cholesterol, liver enzymes, and blood cell counts.
Because of these risks, the FDA limits JAK inhibitors to patients who haven’t responded to, or can’t tolerate, at least one other type of advanced therapy. They require a careful risk-benefit conversation, particularly for older adults and people with cardiovascular risk factors.
Who Qualifies for an Oral Treatment
Oral eczema medications aren’t the starting point for treatment. The typical path begins with moisturizers and topical steroids, then moves to stronger prescription creams or ointments if those aren’t enough. If your eczema covers large areas of your body, keeps flaring despite consistent topical treatment, or significantly affects your sleep and daily life, you enter the category where systemic (whole-body) treatments become appropriate.
At that stage, your dermatologist will weigh several factors: how severe your eczema is, which treatments you’ve already tried, your age, other health conditions you have, and your comfort level with the monitoring that oral medications require. Some people prefer a daily pill over a biweekly injection. Others may have reasons to avoid JAK inhibitors and do better with an older immunosuppressant. The conversation is genuinely individualized at this level of treatment.
For children with severe eczema, options are more limited. The newer JAK inhibitors are approved for adults, while the older immunosuppressants like cyclosporine and methotrexate are used in pediatric cases, though with careful dosing and monitoring. Your child’s dermatologist can walk through what makes sense given their age and disease severity.